Prognosis

A mesothelioma diagnosis comes with many important questions. Perhaps the most crucial question is – what is the prognosis? In fact, the prognosis of mesothelioma varies depending on a number of variables. These variables include:

1. The patient – their age, biology, and state of health
2. The cancer – has the mesothelioma spread or is it localized when it is diagnosed and what is the cell type
3. The treatment or treatments selected
4. The expertise of the treatment team (doctors and other clinicians)

The Patient’s Health

A patient’s general state of health is an important prognostic factor in fighting any disease and mesothelioma is no exception. In addition, a patient’s biology or physiology also plays a role. For example, will chemotherapy work or can it be tolerated? Does the patient have a heart condition so that surgery is not an option? How will the patient’s biology interact with the treatment? The answers to these questions can all play a role in the prognosis.

The Cancer

The spread or lack of spread of the cancer is also an important factor. If mesothelioma is localized it can be easier to treat. In fact, surgery is usually only an option if the cancer has not metastasized. If it has spread then treatment options may be more limited. In addition, there are three cell types of mesothelioma – epithelioid, biphasic, and sacramatoid. The first, epithelioid, often has the best prognosis of the three.

The Treatment

The treatment or therapies selected is also important. Patients can select from conventional therapies (radiation, chemo, and surgery), clinical trials or integrative or alternative modalities. Not every therapy works in every patient. There is an important connection between a person’s physiology, cancer and the treatments selected. The interchange or intersection of these three factors often dictate what the treatment outcome and prognosis will be. Unfortunately, it is often difficult to predict because how a tumor or a treatment acts in a patient’s body is often not known until after the fact.

The Doctors’ Expertise

The last factor is the expertise of your doctors or licensed care givers. How these people do their jobs can be a key factor in prognosis. Are the surgeons experienced with mesothelioma? For example, what is their mortality rate for surgery? The smallest rate bodes better than the highest rate. Also, what options can these treaters suggest? Do they only offer chemo or can they offer a wide range of different modalities and treatment options. All these factors play a role in the prognosis of mesothelioma.

Below are some more details about the prognosis for mesothelioma.

Prognosis of Pleural Mesothelioma

The prognosis of pleural mesothelioma with standard treatment is typically not great.   Median overall survival is a little over a year.  However, there are a number of factors that affect prognosis.

A number of studies have been performed over the years to determine what treatments are optimum for mesothelioma and what factors lead to a better prognosis. Below, we report on several of these.

In a September 2016 Austrian study, a total of 210 patients with malignant pleural mesothelioma were followed.

• 167 (79.5%) were men and 43 (20.5%) were women
• The average age was 67 at the time of diagnosis
• Asbestos exposure was confirmed in 109 (69.4%) patients
• The majority of patients had epithelioid cell type (67.2%)
• Sarcomatoid comprised 16 (7.6%)
• Biphasic was found in 28 patients (13.3%)
• In 25 patients, the cell type was not specified

Data about survival was available for 185 patients. The study found:

• Median overall survival was 19.1 months.
• Pleural mesothelioma patients with early-stage disease (stages I, II) had an overall survival of 26.4 months.
• Pleural mesothelioma patients with late-stage disease (stages III, IV) had an overall survival of 13.0 months .
• Patients with epithelioid cell type had overall survival of 25.1 months.
• Patients with sarcomatoid or biphasic cell type had overall survival of 10.2 months.
• There was no survival difference between males and females.
• There was no survival difference between patients below or above the age of 65 years.
• Survival was significantly better in patients undergoing surgery. However, these patients were significantly younger, had earlier-stage disease, better performance status, and more often had epithelioid subtype.

The study concluded that factors that indicated a better prognosis included: higher Karnofsky score, earlier stage disease, epithelioid cell type, and surgery within multimodality treatment.

• Management of malignant pleural mesothelioma – part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database. Klikovits T, et al., Wien Klin Wochenschr. 2016 Sep;128(17-18):627-34.

Prognosis of Peritoneal Mesothelioma

The prognosis of peritoneal mesothelioma has become much better with the advent of surgery and HIPEC.  The following studies illustrate the improvements in prognosis over the last several years.

Peritoneal Mesothelioma Prognosis with Chemotherapy

In a 2011 Greek Study, chemotherapy was used to treat peritoneal mesothelioma patients.  Six patients with peritoneal mesothelioma were treated with 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2). Chemotherapy was administered on an outpatient basis every 3 weeks. The estimated median overall survival was 24 months.

• Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Lainakis G, et al., Tumori. 2011 Jan-Feb;97(1):25-9.

Peritoneal Mesothelioma Prognosis with HIPEC

An April 2014 United States Study examined 65 patients with pleural mesothelioma who underwent surgery and HIPEC (hyperthermic intraperitoneal chemoperfusion) between 2001 and 2010.

What is HIPEC for Mesothelioma?

HIPEC is where heated chemotherapy is used to bath the surgical cavity putting the chemo in direct contact where the tumor cells remain.  The study found that overall mesothelioma survival was 46.2 months.  The study also found that although survival was better, there were side effects associated with this treatment approach that included:

• Six percent of the patients died within 60 days.
• Of the 65 patients, 91 % were admitted to the intensive care unit (ICU) postoperatively, with median hospital length of 12 days.
• A total of 12 patients (18 %) underwent reoperation: four patients (33 %) for enteric leak, 1 patient (8 %) for an intra-abdominal abscess, and seven patients (58%) for other reasons.

Factors that contributed to a poor prognosis included:

• Older patient
• More widespread tumors
• More aggressive cell type
• Incomplete surgery
• Post-operative infection

The study concluded that better prognosis is associated with patients who have the epithelioid cell type, lower volume of tumor, and more effective surgery (most tumor removed).

• Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Magge D., et al., Ann Surg Oncol. 2014 Apr;21(4):1159-65.

Next: Treatment

Related Posts

Meta-Analysis Finds Lung-Sparing Surgery the Best Option for Most Mesothelioma Patients - There is now more evidence to support the growing number of experts who favor lung-sparing P/D surgery over radical extrapleural pneumonectomy (EPP) for the treatment of malignant pleural mesothelioma. There has been an ongoing debate within the surgical community over which procedure carries the most benefit with the least risk. The late David Sugarbaker, MD, of Baylor St. Luke’s Medical Center in Houston was a pioneer of the EPP procedure, which involves removing not only the diseased pleural lining where mesothelioma tumors grow, but also the nearest lung, most of the diaphragm, the pericardium, and other at-risk tissues. But it turns out that, although Sugarbaker and his team were able to show a mesothelioma survival benefit with EPP, their results, … Continue reading Meta-Analysis Finds Lung-Sparing Surgery the Best Option for Most Mesothelioma Patients »

Ofev Fails to Boost Mesothelioma Survival in New Study - In the quest to develop new, more effective first-line treatments for malignant pleural mesothelioma, it now looks like Ofev (nintedanib) is out of the running. Phase III results of the LUME-Meso mesothelioma trial are in and they contain some disappointing news for mesothelioma patients and for the drug’s developer, Boehringer Ingelheim. The news is especially disappointing since the results of the Phase II portion of the trial, released last year, looked promising. At that time, researchers reported a survival gain of more than 5 months among the Ofev-treated mesothelioma patients and progression-free survival of four months. But further research did not support those results, as investigators announced to the world’s lung cancer experts at the IASLC 19th World Lung Cancer … Continue reading Ofev Fails to Boost Mesothelioma Survival in New Study »

A Less Formal Approach to Connecting Mesothelioma Patients and Researchers - Mesothelioma researchers in England are experimenting with an innovative way to connect patients and scientists in the quest for a cure. Malignant mesothelioma, the cancer most closely associated with asbestos exposure, is one of the world’s most deadly malignancies. Many patients diagnosed with mesothelioma are given only months to live. Increasingly, clinical research holds great promise for new ways of approaching diseases like mesothelioma, but understanding that research and its implications can be difficult, even when listening to the researchers directly. To bridge the gap, investigators with the June Hancock Mesothelioma Research Fund (JHMRF) in Sheffield, UK have introduced “Meet the Researchers” — a program designed to engage mesothelioma patients and researchers in a more informal way. Mesothelioma Research Can … Continue reading A Less Formal Approach to Connecting Mesothelioma Patients and Researchers »

How Doctors Break Bad News May Impact Mesothelioma Survival - For newly diagnosed mesothelioma patients, having a doctor who is too compassionate could have a negative impact on their survival. Researchers at France’s University of Lille made that seemingly counterintuitive observation as part of the first study of the prognostic role of physician empathy in cancer patients. The results, published in the Journal of Clinical Medicine, suggest that, rather than comforting patients, too much compassion and listening from the oncologist tends to make them worry more about their odds of survival. Physician Attitude and Mesothelioma Outcomes The study involved 179 patients who were diagnosed with lung cancer or pleural mesothelioma between January 2015 and March 2016. Both cancers are difficult to treat and often carry a poor prognosis. This is … Continue reading How Doctors Break Bad News May Impact Mesothelioma Survival »

Lung Fluid Proteins Could be Key to Earlier Mesothelioma Diagnosis - Australian researchers say proteins found in lung fluid could hold the key to diagnosing pleural mesothelioma months or even years before a tumor is visible on imaging scans. Proteins function as communication devices in the body, directing all sorts of critical cellular processes, including the processes that tell cancer cells to begin replicating at a higher rate than normal cells. Scientists at Flinders University, one of the world’s leaders in mesothelioma research, wondered if the proteins that help give rise to malignant pleural mesothelioma could be found in pleural effusions and used as biomarkers to identify the cancer earlier. Looking for Mesothelioma Biomarkers in Lung Fluid In a new study published in the Journal of Proteomics, the team notes that … Continue reading Lung Fluid Proteins Could be Key to Earlier Mesothelioma Diagnosis »

Surgery May Offer Survival Advantage for Rare Mesothelioma Subtypes - People with the most dangerous subtypes of malignant pleural mesothelioma may live longer if they undergo surgery. In an article in the Annals of Thoracic Surgery, University of Arizona researchers say cancer-directed surgery can lengthen survival in people with sarcomatoid and biphasic mesothelioma, two of the hardest cancers to treat. Multiple studies have suggested that there is a survival benefit from surgery in people with epithelioid mesothelioma, the most common subtype. But, the evidence is much more scanty for people with either sarcomatoid or biphasic mesothelioma, both of which are associated with a worse mesothelioma prognosis  and shorter overall survival. Now, the Tucson-based research team says surgery aimed at removing the cancer (rather than just alleviating symptoms) can help these mesothelioma … Continue reading Surgery May Offer Survival Advantage for Rare Mesothelioma Subtypes »

Short Term Mesothelioma Survival Better with Conservative Surgery - Researchers at the Icahn School of Medicine at Mount Sinai have added their voices to the ongoing debate over the best type of surgery for malignant pleural mesothelioma. After a meta-analysis of 30-day mortality among 500 mesothelioma patients, the group has come down on the side of pleurectomy decortication (PD), the more conservative — and less risky — of the two major types of mesothelioma surgery. Mesothelioma Surgery: EPP vs. P/D Pleural mesothelioma, also referred to as asbestos cancer, is notoriously difficult to treat. Successful mesothelioma treatment usually involves a combination of therapies, such as Alimta (pemetrexed), radiotherapy, and curative surgery in patients who are healthy enough to undergo it. (Surgery is currently only recommended for patients with epithelioid mesothelioma, … Continue reading Short Term Mesothelioma Survival Better with Conservative Surgery »

Mesothelioma Survival Has Changed Little in Two Decades in Canada - There was some sobering news out of Canada this week that gives even more urgency to the need to find a cure for malignant mesothelioma. According to data compiled by Statistics Canada, while the net survival of several types of cancer has increased since the early 1990s, there has been little change in mesothelioma survival. Analysis of Cancer Net Survival The report, published in the journal Health Reports, calculated changes in net survival (where cancer is hypothetically the only possible cause of death) of patients with 30 different types of cancer during two 2-year time periods — 1992 to 1994 and 2012 to 2014. After factoring for age-related changes, the report analyzes differences in the five-year survival rates of patients … Continue reading Mesothelioma Survival Has Changed Little in Two Decades in Canada »

Advanced Computer Program Might Pinpoint Mesothelioma Sooner - Scientists at New York University School of Medicine have successfully used a sophisticated computer program to distinguish between different types of lung cancer and identify the mutated genes behind them. The developers say the technology could open the door to faster diagnosis of other types of cancer, including malignant mesothelioma. Malignant Mesothelioma, the Asbestos Cancer Malignant pleural mesothelioma is a form of lung cancer caused by asbestos exposure. Instead of starting in the lung tissue like other types of lung cancer, it grows on the membrane that surrounds the lungs and can then spread to the lungs and other organs. There is no cure and the prognosis for mesothelioma is usually poor. As with most types of cancer, earlier diagnosis … Continue reading Advanced Computer Program Might Pinpoint Mesothelioma Sooner »

Mobile App Could Help Mesothelioma Patients Find New Treatments - Mesothelioma patients now have a high-tech new way to connect with cutting edge mesothelioma treatments around the world – for a price. A pair of Harvard-trained oncologists have just rolled out a new app that promises to connect people who have cancers like pleural mesothelioma with treatments and clinical trials that even their physicians may not be aware of. The app, called Driver, is being rolled out this week in the US and China in the wake of a trial run with a hundred people over the past year. How Might Driver Help Mesothelioma Patients? One of the biggest obstacles faced by patients diagnosed with rare cancers like pleural or peritoneal mesothelioma is getting the most up-tp-date information about potential … Continue reading Mobile App Could Help Mesothelioma Patients Find New Treatments »